查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1729655

日本糖尿病市場報告：2025-2033

Japan Diabetes Market Report: 2025-2033
出版日期: | 出版商: IMARC | 英文 122 Pages | 商品交期: 5-7個工作天內

價格

2024 年日本糖尿病市場規模達 56 億美元。展望未來， IMARC Group預計到 2033 年市場規模將達到 74 億美元，2025-2033 年期間的成長率 (CAGR) 為 3.2%。市場的主要促進因素是老年人口的成長、糖尿病盛行率的上升、政府支持措施帶來的醫療支出的增加以及治療方案的技術進步。

日本糖尿病市場分析：

  • 主要市場促進因素：由於生活方式的改變和人口老化，日本糖尿病盛行率上升是主要的成長誘因。此外，最近的研究表明，糖尿病患者數量仍在成長，這增加了日本糖尿病市場的需求。此外，政府也資助並實施了多項健康舉措，以加強糖尿病的治療和管理。其中包括糖尿病治療補助和鼓勵市場擴張的公共衛生措施。
  • 主要市場趨勢：胰島素幫浦和連續血糖監測儀（CGM）等先進的糖尿病護理技術越來越受歡迎。此外，市場正見證著個人化治療計劃和定製藥物的趨勢，這是由對遺傳變量和獨特患者需求的更多研究推動的，以提供更高效和專業化的糖尿病管理解決方案。
  • 競爭格局：日本糖尿病市場由大型國際製藥和醫療器材企業主導，因為他們廣泛的產品和尖端技術幫助他們保持競爭力。此外，日本公司也針對日本患者的需求提供創新和客製化解決方案。
  • 挑戰與機會：市場挑戰包括嚴格的監管規定和新型糖尿病療法的漫長核准程序。另一方面，老年人口的不斷成長為專門針對這一人群的糖尿病治療和管理計劃的發展提供了巨大的機會。此外，遠距醫療和行動健康應用等數位健康技術的發展為更好地參與患者和糖尿病管理創造了新的可能性。

日本糖尿病市場趨勢：

糖尿病盛行率上升

日本糖尿病市場的成長是由糖尿病發病率的上升所推動的。根據國際糖尿病聯盟（IDF）的報告，截至 2021 年，該國糖尿病患者人數為 93,187,400 人，成年人糖尿病盛行率為 11.8%，即 11,004,999 例。因此，由於對包括尖端藥物和監測設備在內的完整糖尿病護理解決方案的需求不斷增加，市場正在不斷擴大。此外，隨著患者數量的增加，製藥公司和醫療保健專業人員被迫創造和提供各種各樣的治療方案，以滿足患者的不同需求。此外，糖尿病病例的增加也增加了針對糖尿病的專門醫療服務，試圖改善患者的治療效果和生活品質。因此，這一趨勢推動了抗糖尿病藥物的銷售，並促進了創新血糖監測技術市場的發展，這些技術有望提供更準確、更人性化的選擇，從而為日本糖尿病市場創造了積極的前景。

老年人口不斷增加

根據總務省報道，截至2023年9月15日，日本65歲以上的老齡人口數已達3,622.7萬人，佔總人口的比例將增加0.1個百分點，達到29.1%，創歷史新高。此外，老年人更容易患第 2 型糖尿病，這增加了對專門的糖尿病管理計劃和產品的需求。人口結構的這種變化促使醫療保健組織和臨床醫生專注於老年糖尿病的治療，從而推動了針對老年人群需求的藥物治療、營養指導和患者教育的進步。此外，人口老化影響了多種需求服務和產品，這些服務和產品使用簡單、侵入性低，非常適合老年患者，並增加了必要的糖尿病治療量。

政府支持措施和醫療支出

糖尿病市場受到日本政府積極推動的醫療保健支出政策的推動，其中包括用於治療糖尿病等慢性疾病的大量預算。根據Frontiers統計，2020年，日本全國醫療支出飆升至43兆日圓（3,040億美元），幾乎是1990年以來的兩倍。這意味著該國國內生產毛額的成長從4.6%上升到8.0%。此外，政府確保在糖尿病護理方面投入足夠的資金，使治療更加容易獲得且價格更合理。這些項目涵蓋了從複雜的治療選擇到初級預防的所有內容，糖尿病護理的基礎正在改善。此外，政府採取了許多舉措，集中進行篩檢和公共衛生運動，以降低糖尿病的盛行率，同時改善社區層面的糖尿病管理，這些舉措正在影響市場的成長。因此，這些全面的健康政策透過提高意識和早期發現，同時將先進的糖尿病照護納入公共衛生系統，支持日本糖尿病市場的成長。

日本糖尿病市場細分：

按細分市場分類：

  • 口服抗糖尿病藥物
  • 胰島素

胰島素佔大部分市場佔有率

由於老齡人口中糖尿病的盛行率不斷上升，以及為有效管理血糖而擴大採用胰島素療法，胰島素佔據了相當大的市場佔有率。此外，以高效著稱的日本醫療保健系統大力支持糖尿病護理，使人們能夠廣泛獲得胰島素治療。此外，市場也受惠於胰島素配方和輸送系統的進步，從而提高了患者的依從性和治療效果。此外，日本政府積極的健康措施旨在提高人們對糖尿病的認知和篩檢，進一步推動了對胰島素的需求。此外，該領域的成長還得益於國內製藥公司與全球糖尿病護理領導者之間的合作，旨在創新和擴大針對日本患者獨特需求的尖端胰島素解決方案的可用性。因此，主要參與者正在推出先進的產品變體來滿足這些需求。例如，2023 年 3 月，Health2Sync 在日本東京和台灣台北宣布其 Health2Sync 應用程式的最新更新，現在包括來自 Mallya Cap 的胰島素資料，Mallya Cap 是由 Biocorp 製造並由諾和諾德在日本銷售的胰島素筆連接設備。此次合作是世界上首次整合此類資料，旨在透過追蹤各種健康指標（例如胰島素注射記錄）來幫助接受胰島素治療的患者。由於這些創新，日本糖尿病市場預測顯示胰島素領域將繼續佔據市場主導地位。

日本糖尿病市場新聞：

  • 2023 年 4 月 18 日，日本禮來公司和田邊三菱製藥株式會社 (MTPC) 宣佈在日本推出 Mounjaro 皮下注射劑 2.5 毫克/5 毫克 ATEOS，這是一種有前途的 2 型糖尿病治療替代方案。
  • 2024 年 5 月 22 日，三菱化學集團旗下、總部位於日本大阪中央區的田邊三菱製藥株式會社 (MTPC) 宣布推出 SGLT2 抑制劑 CANAGLU(R) OD 片劑 100 毫克，為第 2 型糖尿病提供新的治療選擇。 CANAGLU(R) OD 片劑只需少量水分（如唾液）即可快速崩解，更容易吞嚥。此功能對於需要持續服藥的 2 型糖尿病患者特別有益，因為它提高了治療的便利性和依從性。

本報告回答的關鍵問題：

  • 日本糖尿病市場目前表現如何？未來幾年又將如何表現？
  • COVID-19 對日本糖尿病市場有何影響？
  • 日本糖尿病市場按細分如何分類？
  • 日本糖尿病市場的價值鏈分為哪些階段？
  • 日本糖尿病市場的主要促進因素和挑戰是什麼？
  • 日本糖尿病市場的結構是怎麼樣的？主要參與者是誰？
  • 日本糖尿病市場的競爭程度如何？

本報告回答的關鍵問題：

  • 日本糖尿病市場目前表現如何？未來幾年又將如何表現？
  • COVID-19 對日本糖尿病市場有何影響？
  • 日本糖尿病市場按細分如何分類？
  • 日本糖尿病市場的價值鏈分為哪些階段？
  • 日本糖尿病市場的主要促進因素和挑戰是什麼？
  • 日本糖尿病市場的結構是怎麼樣的？主要參與者是誰？
  • 日本糖尿病市場的競爭程度如何？

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

  • 概述
  • 主要行業趨勢

第5章：糖尿病疾病概述

  • 什麼是糖尿病？
  • 糖尿病診斷與治療
    • 診斷
    • 治療
  • 糖尿病併發症

第6章：日本糖尿病流行病學

  • 糖尿病人口和盛行率
  • 人口及盛行率：依糖尿病類型（1型和2型）
  • 人口及盛行率：按地區
  • 人口及盛行率：依性別
  • 人口及盛行率：依年齡層

第7章：日本糖尿病市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測
  • SWOT分析
  • 價值鏈分析
  • 波特五力分析
  • 市場區隔：按細分市場

第8章：競爭格局

  • 市場結構
  • 關鍵參與者簡介
Product Code: SR112025A561

The Japan diabetes market size reached USD 5.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 7.4 Billion by 2033, exhibiting a growth rate (CAGR) of 3.2% during 2025-2033. The market is primarily driven by the growing geriatric population, increased prevalence of diabetes, enhanced healthcare spending with supportive government initiatives, and technological advancements in treatment options.

Japan Diabetes Market Analysis:

  • Major Market Drivers: The rising prevalence of diabetes in Japan due to the changing lifestyles and an aging population represents a major growth-inducing factor. In addition, recent research indicates that the diabetic patient population is still growing, which is increasing the Japan diabetes market demand. Besides, the government has funded and executed several health initiatives to enhance the treatment and management of diabetes. These include diabetes treatment subsidies and public health initiatives that encourage market expansion.
  • Key Market Trends: Advanced diabetes care technology like insulin pumps and continuous glucose monitors (CGMs) are becoming more popular. Moreover, the market is witnessing a trend toward individualized treatment plans and customized medicines, which is driven by greater research into genetic variables and unique patient demands to deliver more efficient and specialized diabetes management solutions.
  • Competitive Landscape: The Japanese diabetes market is dominated by giant international pharmaceutical and medical device businesses, as their wide range of products and cutting-edge technology help them to stay competitive. Additionally, Japanese companies are offering innovations and customized solutions specific to the requirements of Japanese patients.
  • Challenges and Opportunities: Challenges in the market include stringent regulatory regulations and protracted approval procedures for novel diabetic therapies. On the other hand, the growing geriatric population offers substantial opportunities for the development of diabetes treatment and management programs specifically designed for this demographic. Besides, the development of digital health technologies, such as telemedicine and mobile health apps, creates new possibilities for better patient engagement and diabetes management.

Japan Diabetes Market Trends:

Rising Diabetes Prevalence

The growth of the diabetes market in Japan is driven by the rising incidence of diabetes. According to the International Diabetes Federation (IDF) reports, with 93,187,400 individuals in the country as of 2021, the prevalence rate of diabetes is 11.8% or 11,004,999 cases among adults. As a result, the market is expanding due to the increasing need for complete diabetes care solutions, which include cutting-edge drugs and monitoring equipment. Moreover, pharmaceutical businesses and healthcare professionals are compelled by the increasing number of patients to create and offer a wide array of treatment alternatives that address the diverse demands of their patients. In addition, the rise in diabetes cases has increased diabetes-specific healthcare services that attempt to enhance patient outcomes and quality of life. Hence, this trend has propelled the sales of anti-diabetic medications and boosted the market for innovative glucose monitoring technologies that promise more accurate and user-friendly options, thus creating a positive Japan diabetes market outlook.

Growing Geriatric Population

As reported by the Ministry of Internal Affairs and Communications, Japan's elderly population, those aged 65 and above, reached 36,227 thousand as of September 15, 2023. Moreover, the proportion of seniors in the overall population increased by 0.1% points to 29.1%, the highest percentage ever recorded. Additionally, the elderly are more susceptible to type 2 diabetes, which escalates the need for specialized diabetes management programs and products. This change in the population motivates healthcare organizations and clinicians to concentrate on the treatment of geriatric diabetes, resulting in advancements in medication therapy, nutritional guidance, and patient education customized to the needs of the geriatric population. Besides, the aging population influences several services and products that are in demand, offer simple use and low invasiveness, which are ideal for senior patients, and increase the volume of diabetic treatments that are necessary.

Supportive Government Initiatives and Healthcare Spending

The diabetes market is driven by the government of Japan's aggressive approach to healthcare spending, which includes a sizeable budget for treating chronic illnesses like diabetes. According to Frontiers, in 2020, Japan's national medical spending skyrocketed to 43 Trillion yen (304 Billion USD), nearly doubling from past figures since 1990. This indicates an increase in the nation's gross domestic output from 4.6% to 8.0%. In addition, the government ensures that enough money is spent on diabetes care, which makes treatments more accessible and reasonably priced. The foundation of diabetes care is being improved due to these programs, which cover everything from sophisticated treatment choices to primary prevention. In addition, numerous government initiatives concentrated on screenings and public health campaigns to lower the prevalence of diabetes while improving its management at the community level are influencing the market growth. Hence, these comprehensive health policies support Japan diabetes market growth by increasing awareness and early detection while integrating advanced diabetes care into the public health system.

Japan Diabetes Market Segmentation:

Breakup by Segment:

  • Oral Antidiabetics
  • Insulin

Insulin accounts for the majority of the market share

Insulin reflects a substantial portion of the market share due to the increasing prevalence of diabetes among the aging population and the rising adoption of insulin therapies for effective glucose management. Additionally, Japan's healthcare system, renowned for its efficiency, extensively supports diabetes care, enabling widespread access to insulin treatments. Moreover, the market benefits from advancements in insulin formulations and delivery systems, which enhance patient adherence and outcomes. Besides, the Japanese government's proactive health initiatives aim to improve diabetes awareness and screening, further driving the demand for insulin. Furthermore, this segment's growth is also fueled by collaborations between domestic pharmaceutical companies and global diabetes care leaders, aiming to innovate and expand the availability of cutting-edge insulin solutions tailored to the unique needs of Japanese patients. Hence key players are introducing advanced product variants to meet these needs. For instance, in March 2023, in Tokyo Japan, and Taipei, Taiwan, Health2Sync, announced the recent update of its Health2Sync App now including insulin data from the Mallya Cap, a connected device for insulin pens created by Biocorp and marketed in Japan by Novo Nordisk. This collaboration introduces the world's first integration of this type of data and is designed to aid patients undergoing insulin treatment by tracking various health metrics, such as insulin injection records. Due to these innovations, the Japan diabetes market forecast states that insulin segment will continue to dominate the market.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have been provided.
  • At present, key players in the market are actively enhancing growth through strategic collaborations, advanced research and development (R&D) initiatives, and educational programs to improve diabetes management. Additionally, companies like Novo Nordisk and Sanofi are investing heavily in the development of next-generation insulin therapies and glucose monitoring systems tailored to meet the specific needs of Japanese patients, thus accounting for the Japan diabetes market share. These firms collaborate closely with local healthcare providers to ensure broad distribution and integration of their products into daily medical practice. Furthermore, these market leaders support extensive patient education campaigns to increase awareness about diabetes symptoms, treatment options, and lifestyle adjustments necessary for effective disease management. These comprehensive strategies strengthen their market position and significantly contribute to improving patient outcomes in Japan. For instance, on 29 March 2023, Maryland, Astellas Pharma Inc. announced its partnership with Roche Diabetes Care Japan Co., Ltd. This partnership focuses on the development and commercialization of the globally recognized Accu-Chek Guide Me blood glucose monitoring system, noted for its high accuracy, in conjunction with BlueStar(R)*1. BlueStar, an FDA-approved digital health solution for managing diabetes, is developed by Welldoc, Inc. and is available in the U.S. and Canada. Astellas and Welldoc are collaboratively advancing BlueStar's development in Japan. Astellas plans to seek regulatory approval and reimbursement for this integrated medical product in the future.

Japan Diabetes Market News:

  • 18 April 2023, Eli Lilly Japan and Mitsubishi Tanabe Pharma Corporation (MTPC) have declared the introduction of the Mounjaro subcutaneous injection 2.5 mg / 5 mg ATEOS in Japan which represents a promising treatment alternative for type 2 diabetes.
  • 22 May 2024, Mitsubishi Tanabe Pharma Corporation (MTPC), part of the Mitsubishi Chemical Group and headquartered in Chuo-ku, Osaka, Japan, announced the release of the SGLT2 inhibitor CANAGLU(R) OD Tablets 100 mg, to provide a new treatment option for type 2 diabetes mellitus. The CANAGLU(R) OD Tablets are designed to disintegrate quickly with just a slight amount of moisture, such as saliva, facilitating easier ingestion. This feature is particularly beneficial for individuals with type 2 diabetes requiring continuous medication, as it enhances convenience and adherence to treatment.

Key Questions Answered in This Report:

  • How has the Japan diabetes market performed so far, and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan diabetes market?
  • What is the breakup of the Japan diabetes market on the basis of segment?
  • What are the various stages in the value chain of the Japan diabetes market?
  • What are the key driving factors and challenges in the Japan diabetes market?
  • What is the structure of the Japan diabetes market, and who are the key players?
  • What is the degree of competition in the Japan diabetes market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Diabetes Disease Overview

  • 5.1 What is Diabetes?
  • 5.2 Diabetes Diagnosis and Treatment
    • 5.2.1 Diagnosis
    • 5.2.2 Treatment
  • 5.3 Diabetes Complications

6 Japan Diabetes Epidemiology

  • 6.1 Diabetes Population and Prevalence Rates
  • 6.2 Population and Prevalence Rates by Diabetes Type (Type-1 and Type-2)
  • 6.3 Population and Prevalence Rates by Region
  • 6.4 Population and Prevalence Rates by Gender
  • 6.5 Population and Prevalence Rates by Age Group

7 Japan Diabetes Market

  • 7.1 Market Overview
  • 7.2 Market Performance
  • 7.3 Impact of COVID-19
  • 7.4 Market Forecast
  • 7.5 SWOT Analysis
    • 7.5.1 Overview
    • 7.5.2 Strengths
    • 7.5.3 Weaknesses
    • 7.5.4 Opportunities
    • 7.5.5 Threats
  • 7.6 Value Chain Analysis
  • 7.7 Porter's Five Forces Analysis
    • 7.7.1 Overview
    • 7.7.2 Bargaining Power of Buyers
    • 7.7.3 Bargaining Power of Suppliers
    • 7.7.4 Degree of Competition
    • 7.7.5 Threat of New Entrants
    • 7.7.6 Threat of Substitutes
  • 7.8 Market Breakup by Segment
    • 7.8.1 Japan Oral Antidiabetics Market
      • 7.8.1.1 Historical Market Trends
      • 7.8.1.2 Market Breakup by Class
      • 7.8.1.3 Market Shares of Key Players
      • 7.8.1.4 Market Forecast
    • 7.8.2 Japan Insulin Market
      • 7.8.2.1 Historical Market Trends
      • 7.8.2.2 Market Breakup by Class
      • 7.8.2.3 Market Shares of Key Players
      • 7.8.2.4 Market Forecast

8 Competitive Landscape

  • 8.1 Market Structure
  • 8.2 Profiles of Key Players

List of Figures

  • Figure 1: The Impact of Diabetes in the Human Body
  • Figure 2: Diabetes Complications
  • Figure 3: Global: Breakup of Diabetes Patients by Region, (in %) 2024 & 2033
  • Figure 4: Body Mass Index and Relative risk of Type-2 Diabetes
  • Figure 5: Japan: Total Number of Diabetes Patients (in 000), 2019-2024
  • Figure 6: Japan: Total Number of Diabetes Patients Forecast (in 000), 2025-2033
  • Figure 7: Japan (Type1 & Type2): Total Number of Diabetes Patients (in 000), 2019-2024
  • Figure 8: Japan (Type1 & Type2): Total Number of Diabetes Patients Forecast (in 000), 2025-2033
  • Figure 9: Japan (Urban & Rural): Total Number of Diabetes Patients (in 000), 2019-2024
  • Figure 10: Japan (Urban & Rural): Total Number of Diabetes Patients Forecast (in 000), 2025-2033
  • Figure 11: Japan (Male & Female): Total Number of Diabetes Patients (in 000), 2019-2024
  • Figure 12: Japan (Male & Female): Total Number of Diabetes Patients Forecast (in 000), 2025-2033
  • Figure 13: Japan: Total Number of Diabetes Patients by Age Group (20-39), (40-59) & (60-79) (in 000), 2019-2024
  • Figure 14: Japan: Total Number of Diabetes Patients Forecast by Age Group (20-39), (40-59) & (60-79) (in 000), 2025-2033
  • Figure 15: Japan: Diabetes Drug Industry Overview
  • Figure 16: Japan: Diabetes Drug Market: Sales Value (in Billion USD), 2019-2024
  • Figure 17: Japan: Diabetes Drug Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 18: Japan: Diabetes Drug Market: SWOT Analysis
  • Figure 19: Japan: Diabetes Drug Market: Value Chain Analysis
  • Figure 20: Japan: Diabetes Drug Market: Porters Five Forces Analysis
  • Figure 21: Japan: Diabetes Drug Market: Breakup of Insulin and Oral Antidiabetics (in %), 2019-2024
  • Figure 22: Japan: Diabetes Drug Market Forecast: Breakup of Insulin and Oral Antidiabetics (in %), 2025-2033
  • Figure 23: Japan: Oral Antidiabetics Market: Sales Value (in Million USD), 2019-2024
  • Figure 24: Japan: Oral Antidiabetics Market: Sales Share of Key Classes (in %), 2019 & 2024
  • Figure 25: Japan: Oral Anti-diabetics Market: Sales Share of Key Players (in %)
  • Figure 26: Japan: Oral Antidiabetics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Japan: Insulin Market: Sales Value (in Million USD), 2019-2024
  • Figure 28: Japan: Breakup of Insulin Market by Class (in %), 2024
  • Figure 29: Japan: Insulin Market: Sales Share of Key Players (in %)
  • Figure 30: Japan: Insulin Market Forecast: Sales Value (in Million USD), 2025-2033

List of Tables

  • Table 1: Diagnosis of Diabetes
  • Table 2: Global: Diabetes Population Breakup by Country (in 000's), 2024 and 2033
  • Table 3: Japan: Total Prevalence & Number of Diabetes Patients, 2019, 2024 & 2033
  • Table 4: Japan (Type1 & Type2): Total Prevalence & Number of Diabetes Patients, 2019, 2024 & 2033
  • Table 5: Japan (Urban & Rural): Total Prevalence & Number of Diabetes Patients, 2019, 2024 & 2033
  • Table 6: Japan (Male & Female): Total Prevalence & Number of Diabetes Patients, 2019, 2024 & 2033
  • Table 7: Japan: Total Prevalence & Number of Diabetes Patients by Age Group (20-39, 40-59, 60-79 - in Millions), 2019, 2024 & 2033
  • Table 8: Japan: Diabetes Drug Market: Competitive Structure